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Aims/Hypothesis: Previous studies have associated serum ferritin levels with type 2 diabetes, so it's well
recognised that there is a subset of patients with type 2 diabetes and also with elevated serum ferritin.
The aim of this pilot study was to test whether venesection is a viable treatment option for patients with
type 2 diabetes.
Methods: Four cases with elevated serum ferritin and type 2 diabetes were subjected to monthly
venesection for 3e9 months, and monitored 3 monthly for serum ferritin and glycated haemoglobin
(HbA1c).
Results: In all four cases, serum ferritin was dramatically reduced, and the HbA1c was reduced in all but
one case, which was a diet-only controlled patient with diabetes and had near normal HbA1c. In two
cases, HbA1c was reduced by 2e3% units (22e33 mmol/mol), making it superior to any current
medication.
Conclusions/Interpretation: Venesection was used here successfully with oral pharmacotherapy, thereby
avoiding the use of insulin. Findings of this study may provide clinicians a powerful new tool to intervene
in the pathological process of type 2 diabetes by a very simple manoeuvre - venesection. These results
need to be repeated and validated in a larger trial as a priority.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
High serum ferritin associated with type 2 diabetes is not rec-
ognised as an entity in the current clinical guidelines for the
management of type 2 diabetes [1]. In 1997, a cross-sectional
population study showed that mildly elevated serum ferritin was
associated with elevated fasting serum insulin [2]. This means that
people with the higher serum ferritin needed to produce more
insulin to remain normoglycemic. In 2008, Le and co-workers
suggested that serum ferritin concentration could be used as a
predictor for diabetes [3], and a meta-analysis has since showed
that elevated levels of serum ferritin may help to identify in-
dividuals at risk of type 2 diabetes [4]. In 2002 a study looking at
blood letting (venesection) in high ferritin type 2 diabetes
demonstrated decreased glycated haemoglobin (HbA1c) levels and
changes to both insulin secretion and insulin resistance [5].edical Innovation, School of
ology, Brisbane, Australia.
Wilson).
Inc. This is an open access article uVenesection is the treatment of choice for iron overload condi-
tions - haemachromatosis, polycythemia rubra vera, polycythemia
cutaneous tarda and clinical iron overload - supported by FerriScan
MRI or liver biopsy. Elevated serum ferritin is commonly encoun-
tered in general practice and 90% of elevated serum ferritin is due to
non-iron overload conditions where venesection is not the treat-
ment of choice. These conditions are chronic alcohol consumption,
metabolic syndrome, obesity, diabetes, malignancy, infection and
inﬂammatory conditions [6]. In these conditions serum ferritin
ranges between 300 and 1000 mg/l, and in these circumstances the
risk of hepatic iron overload is exceedingly low. The high ferritin/
iron overload diseases venesection protocol is registered by the
Therapeutic Goods Administration (TGA) in Australia (the equiva-
lent of the FDA in the USA) and accessible through the “high
ferritin” application hosted by the Australian Red Cross Blood Bank
(https://highferritin.transfusion.com.au/).
All this information collectively suggests that while iron over-
load is virtually unseen in uncomplicated type 2 diabetes, vene-
section may have important beneﬁts for glucose metabolism, seen
as a decrease in HbA1c [5].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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that puts the assertion of Goot et al. [6] - “venesection is not the
treatment of choice” - to the test. The study design was made with
the view that the procedures were ﬁrst and foremost a clinical
treatment protocol for any patient with type 2 diabetes and
elevated serum ferritin. The expectation was that venesection
would lower the HbA1c, and therefore would be a therapeutic
strategy that could be routinely employed in the management of
type 2 diabetes in general practice/internal medicine.
Four pilot cases are presented to support the need for further
studies to fully establish the utility of venesection as a treatment
option in patients with high serum ferritin and type 2 diabetes.
2. Methods
The venesection and all the tests were routinely performed by
Queensland Medical Laboratories (QML) Pathology, and the meth-
odology for each test is brieﬂy described below. All patients had
monthly venesection and the usual three monthly HbA1c. Monthly
venesection was employed as this is the time required for the body
to completely replace the blood from the last venesection [7]. Hb
was tested at every venesection (and no patients became anaemic)
and with the 3 monthly HbA1c; Hb (FBE), serum ferritin, CRP (to
check for distortions due to inﬂammation), and ANA (to exclude
autoimmune conditions) were assayed. All patients were HFE gene
screened for haemochromatosis.
2.1. HbA1c was assayed on a COBAS INTEGRA 400/400 plus/800
analyser using COBAS INTEGRA hemolyzing reagent Gen.2 with an
anti-coagulated whole blood specimen. All haemoglobin variants
which are glycated at the b-chain N-terminus and which have
antibody-recognizable regions identical to that of HbA1c are
measured by this assay. The HBA1c results are reported in mmol/
mol (as deﬁned by the International Federation of Clinical Chem-
istry - IFCC), and as a % (as deﬁned by the Diabetes Control and
Complications Trial - DCCT) both of which are recorded in this
paper in the format mmol/mol (%), for example 42 mmol/mol
(6.0%).
2.2. Ferritin was assayed on the ADVIA Centaur Ferritin assay
which is a two-site sandwich immunoassay using direct chem-
iluminometric technology, which uses constant amounts of two
anti-ferritin antibodies. The ﬁrst antibody, in the Lite Reagent, is a
polyclonal goat anti-ferritin antibody labeledwith acridinium ester.
The second antibody, in the Solid Phase, is a monoclonal mouse
anti-ferritin antibody, which is covalently coupled to paramagnetic
particles.
2.3. C-reactive protein (CRP) was assayed with the wrCRP latex
reagent - a suspension of uniform polystyrene latex particles coated
with anti-CRP antibody. When serum or plasma containing CRP is
mixed with the latex reagent, agglutination takes place resulting in
an increase in the turbidity. This turbidity was measured at 571 nm.
The CRP concentration in serum or plasma was determined from a
calibration curve that is generated with the calibrators.
2.4. ANA was assayed with the Medizinische Labordiagnostika
AG, Euroimmun Indirect Immunoﬂuorescence method, which uti-
lises 2 substrates - a human epithelial cell line (Hep-20-10) and
frozen primate liver e in order to cover all the potential nuclear
antigens. It detects autoantibodies against cell nuclei and is an
important diagnostic indicator in many autoimmune diseases.
2.5. FBE (full blood examination) that includes Hb (haemoglo-
bin) was assayed with a Sysmex XE-2100 which utilises ﬂuorescent
ﬂow cytometry and hydrodynamic focusing technologies to
differentiate normal RBC (red blood cells), WBC (white blood cells)
and platelet populations.
2.6. HFE genotyping for haemachromatosis (C282Y (c.845G > A),
H63D (c.187C > G) and S65C (c.193A > T)) was performed in a NATAaccredited QML laboratory by real-time PCR and melt curve anal-
ysis using ﬂuorescent resonance energy transfer (FRET) probes.
2.7. Venesection was performed according to a standard proto-
col with the patient supine, utilising an upper armveinwith a blood
pressure cuff applied to 80 mmHg to insert the needle and then
reduced to 40 mmHg. The blood collecting bag was placed below
the level of the arm to allow the collection of 450 ml of blood. The
cuff was deﬂated, the needle removed, the puncture site dressed,
and the blood and bag disposed of into the hazardous waste. This
equates to the removal of elemental iron in the order of 250 mg.
3. Results
Throughout the course of this study none of the 4 patients
became anaemic (the haemoglobin values were Case 1e124 g/l,
Case 2e133 g/l, Case 3e146 g/l and Case 4e136 g/l) or had co-
existing clinically signiﬁcant inﬂammatory or auto-immune con-
ditions, as measured by CRP and ANA respectively. Three of the 4
cases were heterozygous for the haemochromatosis gene, the de-
tails of which will be discussed with each case. Mild iron overload
has been demonstrated in the minority of patients with genotypes
such as H63D homozygotes or compound heterozygotes (C282Y/
H63D) [8], however, with only one copy of a defective gene, serum
ferritin is not expected to be elevated above the normal population.
3.1. Case 1 was a 59 year old woman with long-standing diet
controlled type 2 diabetes. She was heterozygous for the haemo-
chromatosis (HFE) H63D (c. 187C > G) mutation. Her initial HbA1c
was 6.5% (47 mmol/mol), but she had been able to keep good
control of her diabetes with diet, with her HbA1c ranging between
6.0% (42 mmol/mol) and 6.3% (45 mmol/mol) over the last 3 years.
At the time of the ﬁrst venesection her serum ferritin was 524 mg/L
and her HbA1cwas 6.1% (43mmol/mol) (Fig.1A). Nine venesections
later, her serum ferritin was 52 mg/L and her HbA1c was 6.0%
(42 mmol/mol).
3.2. Case 2 was a 47 year old woman who has had type 2 dia-
betes for at least 5 years and for some of that time was under
specialist management. About 2 years prior to this study her HbA1c
was at 8.9% (74 mmol/mol) and at the time of the study she was
medicated with gliclazide 120 mg (Diamicron MR) and sitagliptin
XR 50 mg with metformin 850 mg (Janumet), both in the morning.
She was heterozygous for both H63D (c.187C > G) and S65C
(c.193A > T) HFE gene mutations. Her initial serum ferritin was
376 mg/L (mildly elevated above the top of the normal range of 320)
and her HbA1c was 7.9% (63 mmol/mol). After 6 venesections, her
serum ferritin was 71 mg/L and her HbA1c was 6.7% (50 mmol/mol)
(Fig. 1B). This is a drop in HbA1c of 1.2% (13 mmol/mol), which is at
least equivalent to adding another medication, and was her lowest
recorded HbA1c. Ongoing monitoring of these parameters is clearly
required for this lady.
3.3. Case 3 was a 52 year old man whose last HbA1c reading a
year prior to this study was 6.3% (45 mmol/mol). He was taking
alogliptin12.5 mg with metformin1000 mg (NesinaMet) twice
daily, and did not have any HFE mutations. At the time of vene-
section his serum ferritin was 412 mg/L and his HbA1c had jumped
to 9.4% (79 mmol/mol). It is important to appreciate that the pre-
vious HbA1c was 6.3% (45 mmol/mol), so this was a “recent”
elevation and the usual advice here was that he would require in-
sulin therapy from this point on. Instead, 3 venesections later, his
serum ferritin was 49 mg/L and his HbA1c had returned to 6.6%
(49 mmol/mol) (Fig. 1C).
3.4. Case 4 was a 75 year old man whose type 2 diabetes had
beenwell managed for some time on ‘triple therapy’ of pioglitazone
30 mg (Actos) in the morning and sitagliptin XR 50 mg with met-
formin 850 mg (Janumet) twice daily with his HbA1c usually under
6.5% (48 mmol/mol). He was heterozygous for the H63D
Fig. 1. Bar graphs depicting the levels of ferritin (solid bars) and glycated haemoglobin (HbA1c) (open bars) for Cases 1e4 (panels AeD, respectively) before and after their series of
venesections, as indicated.
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serum ferritin was 372 mg/L and his HbA1c was 9.2% (77 mmol/
mol). This againwas a signiﬁcant jump over what had been a stable
background of effective pharmacological management. After three
venesections his serum ferritin was 108 mg/L and his HbA1c was
5.7% (39 mmol/mol) (Fig. 1D).
3.5. As with Case 3, Case 4 experienced an acute deterioration in
his type 2 diabetes, despite what had been stable pharmacological
management. The three venesections saw this massive drop in
HbA1c of 3.5% (38 mmol/mol). Over this period he had put on 4 kg
in weight. He had another 4 venesections and his serum ferritin
dropped to 57. Nine (9) months after the last venesection his HbA1c
was 6.2% (44 mmol/mol), his fasting morning glucose was between
5.3 and 6.7 mg/dL. Capillary BGL was not routinely measured for
clinical reasons but these results show a good correlation between
random glucose concentrations and HbA1c levels at 6.0% (42mmol/
mol).
4. Discussion
To our knowledge, this is the ﬁrst study to use venesection for
the management of type 2 diabetes. Our results have shown thatthe beneﬁt of venesectionmay not be restricted to the iron overload
diseases, however this certainly requires further corroborationwith
a larger study. This pilot study clearly demonstrates a measure of
reversibility to this progressive disease bymodulation of the body's
own physiology/biochemistry rather than with pharmaceutical
agents (drugs), in a similar way that weight loss impacts upon type
2 diabetes.
In Case 1 where the diabetes was well controlled with
diet alone, venesection had an insigniﬁcant impact, or perhaps did
stop the progression of her type 2 diabetes. Case 1 effectively
became a control subject, showing that monthly serial venesection
would not dilute the blood of HbA1c, as her HbA1c never fell below
the 6.0% (42 mmol/mol) level. This is not an absolute baseline
control, but argues against the conjecture that venesection simply
dilutes out the HbA1c and doesn't change the fundamentals of
glycaemic control in the body in this new iron depleted state. It is
very important to remember this control as it provides a solid basis
for evaluating the results of Cases 2 to 4. In Case 2 where the type 2
diabetes was further developed, the effect of bodily iron depletion
was perhaps moderate but nonetheless beneﬁcial. In Case 3 and 4
where the type 2 diabetes had been well managed with the phar-
macological agents up to a point when these oral therapies
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experienced a huge drop in HbA1c of 2.8% (31 mmol/mol), and Case
4 had a drop of HbA1c 3.5% (38 mmol/mol) with no adverse side
effect other than the inconvenience and the discomfort of the
venesection procedures. To their relief, therapy with insulin was
put off for now, and hopefully forever. It seems likely that in these
patients at this point in their disease, body iron overload was
pivotal to the pathological progression of their type 2 diabetes.
Excess iron has been shown to induce diabetes in animal models,
where higher heme iron intake and increased body iron storeswere
signiﬁcantly associated with a greater risk of type 2 diabetes [9]. In
the ob/ob mouse model of type 2 diabetes, dietary iron restriction
or iron chelation protects from diabetes and loss of beta-cell
function [10]. In rat liver and human HepG2 hepatocytes, iron
depletion by deferoxamine up-regulates glucose uptake and insulin
signalling [11]. There is the question of what constitutes normal
iron stores and normal serum ferritin. Case 4 had a dramatic
responsewith his serum ferritin at 108 mg/L, so the upper end of the
normal range at 320 mg/L may need to be re-evaluated in regards to
the effect of this “subtle” iron overload on glycaemic control. The
take home point from this study is the total body depletion of iron
stores with venesection, monitoredwith serum ferritin, generates a
signiﬁcant improvement in glycemic control and thus an
improvement in type 2 diabetes.
While these results alone may be sufﬁcient for the clinician, the
underlying pathobiology warrants further research. The link be-
tween high serum ferritin, and thus the presumption that iron
stores are increased, and the impairment of glycaemic control has
been recognised and studied for more than the past 2 decades. In
addition, the correlation between elevated serum ferritin has been
made with a number of disorders where glucose metabolism is
impaired. This effect for high serum ferritin type 2 diabetes was
elegantly demonstrated in a 2002 study where these effects were
mediated through both insulin secretion and insulin resistance [5].
To the best of our knowledge, there are no quantitative studies that
deﬁne the relative contributions of the components of impaired
glycaemic control, but fortunately there are a lot that describe the
various individual impediments.
From the clinical perspective, we make the assumption that by
the time the diagnosis of type 2 diabetes is made, half the beta-cell
mass has been lost and we are dealing with a progressive and
incurable disease [12]. It has been shown that beta cells are
exquisitely vulnerable to oxidative stress leading to cell death, and
hence catalytically active iron [13]. Thus if we take the beta-cells as
the weak link in the process then the damage to the beta-cells from
accumulated iron may occur by the Fenton reaction which gener-
ates hydroxyl (HO.) and the hydroperoxyl (HOO.) radicals as fol-
lows. (1) Fe2þ þ H2O2/ Fe3þ þ HO. þ OH- and (2)
Fe3þþ H2O2/ Fe2þþ HOO.þ Hþ. (http://en.wikipedia.org/wiki/
Fenton%27s_reagent, [14]) The hydrogen peroxide is generated by
the mitochondria [15] and the free radicals so generated act as
powerful, non-selective oxidants causing intercellular damage, and
presumably cell death over time. The physiological and biochemical
robustness of liver and muscle could lead to the assumption that
these are less important, however the ﬁnding that insulin resis-
tance is improved with iron depletion indicates that glucose
metabolism is also affected at these sites [5]. Electron microscopy
has shown that iron deposits were restricted to beta-cells with
progressive loss of their endocrine granules [16]. It has also been
shown that iron accumulation may be responsible for the impaired
insulin effect and may cause impaired hepatic insulin extraction
[17]. Therefore, while the beta-cells are the likely weak link, there is
a body-wide impairment of glucose metabolism involving beta-
cells, liver and muscle.
It is clear that iron depletion positively impacts upon type 2diabetes, but it is important that glucose metabolism in other
scenarios is also considered, both to support the ﬁndings and
conclusions above, but also to guide research on the effects of iron
depletion in these other circumstances and disease states. In
contradistinction to the clinical guidelines, understanding the role
of functionally signiﬁcant iron overload as measured by serum
ferritin in the scientiﬁc literature is replete. Epidemiologists in
2005 observed that blood donation is associated with decreased
risk of type 2 diabetes (and cardiovascular disease). Blood donation
is simultaneously associated with increased insulin sensitivity and
decreased iron stores, which seems to impact on insulin action,
even in healthy people [18]. The Camden Study published in 2006
found a correlation between elevated serum ferritin concentrations
for pregnant women early in gestation and an increased risk of
gestational diabetes, in part mediated by maternal fat mass and
obesity [19]. A 2009 study identiﬁed that insulin resistance corre-
lated with ferritin levels in premenopausal women [20]. A 2014
meta-analysis of observational studies found that increased ferritin
levels are independently and positively associated with metabolic
syndrome, also termed pre-diabetes [21]. Iron has been shown to
be a risk factor for metabolic syndrome, and phlebotomy of humans
with impaired glucose tolerance and ferritin at the highest quartile
of normal showed improved glucose tolerance [22]. In addition it
has been shown that increased ferritin levels are associated with
the metabolic insulin resistance syndrome [23], and in patients
with metabolic syndrome venesection resulted in improvements in
markers of glycaemic control [24].
The intention of this study was to verify that venesection had a
place in the management of type 2 diabetes in the 21st century. At
the very least it identiﬁes the need for further study. It is imperative
that we widen the net to include womenwith gestational diabetes,
patients with metabolic syndrome, children with type 2 diabetes,
indigenous populations that may have a predisposition for type 2
diabetes (as is the case with the Australian Aboriginal), patients
taking the atypical antipsychotics and even “apparently normal”
individuals with elevated serum ferritin. If we take the view that
moderately elevated serum ferritin, indicative of subtle iron over-
load, is one of the pivotal steps in the pathogenesis of type 2 dia-
betes, then it might be wise to start iron depletion therapy by
venesection as soon as elevated serum ferritin is indicated. Wemay
be able to catch type 2 diabetes before half the beta-cells are lost. If
venesection proved a useful therapeutic tool, then the cost savings
on the oral anti-diabetic agents could be substantial to patients and
governments across the world. Another aspect for further action/
study would be to have a monthly registered venesection schedule
for type 2 diabetic patients with the blood banks, and for this to
become routine practice. In this study all the blood that was taken
was discarded because there was no recognised protocol for
monthly venesection, as is the case for the iron overload diseases as
discussed above. While managing our patients with type 2 diabetes
with venesection, we could also be providing blood banks with
much needed stocks.
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